1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 Jun 2024
Admin
News Article

AstriVax Begins Clinical Trials for Innovative Vaccine Platform Technology

Overview

AstriVax has commenced a Phase I clinical study to assess the safety and effectiveness of its prophylactic vaccines for yellow fever (AVX70120) and rabies (AVX70481) in healthy adults. This initial human trial, called SAFYR, aims to provide essential safety and immunogenicity data, which will be crucial for advancing AstriVax's therapies for chronic infections such as Hepatitis B and human papillomavirus (HPV).

SAFYR Study in Belgium

The SAFYR study is being conducted at two leading vaccine trial sites in Belgium: the Centre for Vaccinology in Ghent and Vaccinopolis in Antwerp. The trial will involve nearly 100 healthy adults aged 18 to 40 to assess the safety and immune response generated by these vaccines. The results are expected to offer clinical validation for the AstriVax vaccine platform.

From AstriVax

AstriVax, noted, “This trial showcases our innovative technology in a clinical proof-of-concept study. We use plasmids to deliver live-attenuated virus vectors with the target viral antigen, creating a self-amplifying mechanism that aims to produce strong and lasting immune responses with minimal doses.”

AstriVax's Revolutionary Vaccines

AstriVax's groundbreaking vaccines are expected to transform the fight against viral pathogens.
They are designed for easy production, have minimal cold chain requirements, and are anticipated to trigger robust, long-lasting immune responses.

About AstriVax

Currently, AstriVax is a clinical-stage company with a strong pipeline targeting viral infections and addressing urgent medical needs, such as chronic Hepatitis B, which affects over 250 million people, and HPV, a major cause of cervical cancer.

AstriVax, reflected, “Less than two years ago, we started with strong academic foundations and secured a €30 million seed round. In May 2023, we received a grant from Flanders Innovation & Entrepreneurship (VLAIO) to further advance our technology. I am incredibly grateful to my exceptional team for their dedication in shaping the company. We expect our chronic Hepatitis B immunotherapy to enter the clinical phase in 2025, marking another significant milestone for AstriVax.”

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!